Inify Laboratories AB — Earnings Release 2025

Aug 27, 2025

Inify Laboratories: Solid growth in Sweden and first patient diagnostics delivered in the UK

Inify Laboratories: Solid growth in Sweden and first patient diagnostics delivered in the UK

STOCKHOLM - August 27, 2025 - Inify Laboratories, a unique laboratory service

that provides cancer diagnostics within pathology, continues to deliver solid

sales growth of 54% in the second quarter, and 83% in the first half of the

year, compared to the same periods last year. Sales in the second quarter

amounted to SEK 5.6 million and the cash balance at the end of the quarter

amounted to SEK 130 million.

"Inify strengthens its position in the Swedish market in prostate cancer

diagnostics. Our current market share in Sweden is now estimated at 10-15%,"

says Fredrik Palm, CEO of Inify Laboratories.

The company's dominant market share in the Stockholm region remains stable, and

a second region in Sweden has now been using their service routinely since the

beginning of the year. Both regions are experiencing significant improvements in

reduced waiting times for patients - a development also confirmed by official

statistics in the Swedish prostate cancer registry. Inify also has ongoing

dialogues with several other regions and remains optimistic about continued

growth in Sweden.

First UK diagnostics delivered

The first UK customer agreement was signed with Park Side Suite, owned by

Frimley Health NHS Foundation Trust, where the first patient diagnostics was

successfully delivered in June. "This marks an important milestone for the

company and demonstrates that we can provide our services from Sweden while

building our local laboratory," says Palm.

Inify is actively engaged in dialogue with the NHS in the UK at both national

and regional levels, as well as with individual hospitals.

"Intensive work is underway to build the new laboratory, dimensioned to be able

to handle the majority of the country's prostate cancer diagnostics," says Palm.

Further development in pathology diagnostics

The company is also continuing its development of gastrointestinal diagnostics.

Solid preparatory work has enabled the system development to progress according

to plan during the second quarter. "Our goal of receiving samples in the second

half of the year remains unchanged - a crucial step in proving our capabilities

in this diagnostic area as well," says Palm.

The global need for modernisation and development within pathology diagnostics,

in order to address both current and future needs in healthcare, is huge.

"We are confident in saying that Inify has taken a leading position in the

development of modern diagnostics. This, in turn, strengthens our belief in our

comprehensive investment plan, which combines geographical expansion with

continued system development for our next diagnostic area," Palm concludes.

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory

services within pathology. It uses a fully digital, standardised and AI

-supported workflow to optimise quality and response times, initially within

prostate.The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to

sample preparation, to reporting by a pathologist. The report is assisted by our

own AI, proven in clinical studies to have world-leading accuracy. The complete

workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off

fromContextVision (https://www.contextvision.com/), with 40 years of experience

within digital imaging for medical applications. The company's share is listed

onEuronext Growth

Oslo (https://live.euronext.com/en/product/equities/SE0017486103-MERK) under the

ticker INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).

For further information, please contact CEO, Fredrik Palm,

fredrik.palm@inify.com, or visit https://www.inify.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.